Respiratory Syncytial Virus (RSV) is a ubiquitous ⁢respiratory pathogen, responsible for a substantial burden of illness across all age groups, but notably dangerous⁤ for infants and older adults.Prior to the development of these vaccines, RSV was the leading cause of bronchiolitis and pneumonia in children under one year ⁣of age, and a significant contributor to serious respiratory illness and hospitalization in adults 65 years and older. The virus spreads through respiratory droplets, making ⁢it highly contagious, especially ⁢during ⁢the fall and winter months.

Historically, management of RSV has been largely supportive, focusing⁢ on hydration and respiratory⁢ support. While monoclonal antibody treatments like nirsevimab offered some protection for ⁢infants,a preventative vaccine was a long-sought goal. The impact of RSV extends beyond individual health, placing a considerable ⁢strain on healthcare systems during peak seasons.